Wolfgang Miesbach Discusses AAV Gene Therapy Safety in Hemophilia B: NEJM Correspondence Highlights Cancer Monitoring
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on Linkedin:
“Happy to Share: Our NEJM Correspondence on AAV Gene Therapy in Severe Hemophilia B is Published Today! I am delighted that our letter to the editor on gene therapy and cancer surveillance—written together Flora Peyvandi and Glenn Pierce —is now published in the New England Journal of Medicine (NEJM)!
This correspondence addresses the recent 13-year follow-up paper by Ulrike Reiss et al., reporting two cancer cases after AAV gene therapy. Importantly, out of the total number of malignancies reported so far in hemophilia gene therapy trials, a relation to gene therapy has always been excluded.
AAV gene therapy offers transformative clinical benefits, but even rare theoretical risks (such as vector integration) require our field to be proactive, and vigilant.
Our comment emphasizes why molecular safety monitoring should go far beyond basic PCR, advocating for robust standards like vector integration mapping and whole-genome sequencing and standardisation of methods is needed.
We also call for harmonized international frameworks (e.g., the WFH-GTR registry) and industry-supported, accessible postmarketing monitoring—ensuring safety without burdening patients.”
Find more information here.
Stay in tune with Hemostasis Today.
-
Aug 22, 2025, 14:58Eric Topol: Covid, Inflammation, and Arterial Aging
-
Aug 22, 2025, 14:57PE Prevention Tip: Surgery, Injury, and Summer Heat
-
Aug 22, 2025, 14:56Lipoprotein(a) as a Prognostic Marker in Atherosclerotic Vascular Disease: Insights from UK Biobank Study
-
Aug 22, 2025, 14:54Negar Asdaghi on Stroke Insights: TNK Fails to Improve CRAO Outcomes
-
Aug 22, 2025, 14:52Wolfgang Miesbach Discusses AAV Gene Therapy Safety in Hemophilia B: NEJM Correspondence Highlights Cancer Monitoring
-
Aug 22, 2025, 04:10Emmanuel J Favaloro Shares 3 Latest Reviews on VTE, DIC, HSCT and Machine Learning
-
Aug 22, 2025, 03:37Lupus Anticoagulant-Hypoprothrombinemia Syndrome: Review by Doris Barcellona and Colleagues
-
Aug 21, 2025, 15:48World Federation of Hemophilia on Inhibitors in Treatment
-
Aug 21, 2025, 14:00Wolfgang Miesbach, Flora Peyvandi and Glenn F Pierce on Malignancy in Persons with Haemophilia
-
Aug 20, 2025, 14:25Mattia Galli: Sex-related Differences in Platelet Reactivity in Patients Both On and Off Antiplatelet Therapy
-
Aug 18, 2025, 23:56Dr. Arun V. J Invites You to His Lecture on ‘AI and Data Sciences in Transfusion Medicine’ at the AI in Healthcare Conclave. Register now!
-
Aug 18, 2025, 23:50Safe and Efficient Thrombectomy with Artix System: Clinical Insights from Neil Desai and Colleagues
-
Aug 16, 2025, 14:42Mark Crowther Honors Davide Matino for Leading Promising Hemophilia Trial at McMaster University
-
Aug 14, 2025, 10:28Impressive 95% Clot Removal in a VTE Case: Symphony16F and Symphony24F Catheters
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Aug 21, 2025, 15:08Global Variations in Blood Collection: What Explains the Differences?
-
Aug 20, 2025, 13:33Askat's Life with Hemophilia A after Access to Prophylactic Treatment Through the WFH Humanitarian Aid Program
-
Aug 19, 2025, 17:22Louise Bannon Encourages You to Support World Thrombosis Day!
-
Aug 17, 2025, 07:31Melissa Korn's story: Recognizing Pulmonary Embolism Symptoms Can Save Lives, NBCA
-
Aug 16, 2025, 14:18Christelle Orlando Highlights Breakthroughs in Thrombophilia Testing and AT Assays at ISTH 2025